A Phase I trial of the alpha particle-emitting radiopharmaceutical, af-001, in patients with differentiated thyroid cancer (papillary carcinoma, follicular carcinoma)
Latest Information Update: 27 Nov 2025
At a glance
- Drugs Af 001 (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alpha Fusion
Most Recent Events
- 27 Nov 2025 New trial record
- 31 Oct 2025 According to Alpha Fusion media release, this clinical trial is designed based on the results of an investigator-initiated Phase I study conducted at The University of Osaka.
- 31 Oct 2025 According to an Alpha Fusion media release, Part Ia of the study will be conducted at the National Cancer Center Hospital East (Principal Investigator: Dr. Makoto Tahara, Chief, Department of Head and Neck Medical Oncology), and Part Ib will be conducted at multiple sites in Japan.